Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2018

View Archived Issues

Inhibitor of alphavbeta6 integrin prevents pre-established biliary fibrosis in BALBc.Mdr2-/- mice

Pulmonary delivery of mRNA encoding antibodies protects mice from RSV infection

MCR1-targeting PET and fluorescence imaging probes for melanoma developed

Mutant c-KIT inhibitor AZD-3229 is equivalent or superior to existing inhibitors in GISTs

Newly identified cell type precedes mast cells in anaphylaxis cascade

RetiPharma secures funding to prepare RP-001 for proof-of-concept study in retinal detachment

Hemostemix develops ACP-01 allogeneic process, begins R&D for NCP-01

Clinical data presented for JNJ-64530440, a novel HBV capsid-assembly modulator, in healthy subjects

MSC-derived EVs reduce inflammatory response and scarring after traumatic spinal cord injury in rats

AN-317, a drug candidate for PD, demonstrates efficacy in vivo

China SFDA clears phase I trial of A-319 in B-cell malignancies

Promising interim results presented from phase IIa study of CTP-543 in patients with alopecia areata

Results from phase IIa study of Zimura plus Lucentis in wet AMD

Swedish Medical Products Agency allows initiation of phase I trial of ROSgard

KalVista designs enlarged phase II study for KVD-900 in HAE

Exploratory clinical studies of NYX-2925 show NMDAr-mediated pharmacodynamic activity

FDA clears PolyPid to begin phase III study of D-PLEX[100]

QBiotics reports first-in-human data for tigilanol tiglate in solid tumors

Effects of tenofovir and tenofovir/levonorgestrel vaginal rings on vaginal microbiota and mucosal PK

Novel rBCG:HIV vaccine candidates with a ChAd.HIV boost show safety and immunogenicity in vivo

sFRP3 as a novel therapeutic target in Alzheimer's disease

Novel HBV capsid formation inhibitor, CB-HBV-001, demonstrates promising safety and PK in vivo

First patient enrolled in phase IIa ALICE study of iadademstat in AML

Nightstar Therapeutics updates status of NSR-RPGR program in X-linked retinitis pigmentosa

Sutro plans phase I trial of STRO-002 following FDA conclusion of IND review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...